Bluebird Bio stock falls after FDA approves gene therapy
Bluebird Bio hits pause on rollout for ill-fated gene therapy Zynteglo as trial flags 2 cancer cases | Fierce Pharma
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
Mergers & Acquisitions - bluebird bio
3 Top Biotech Buyout Candidates in 2021 | The Motley Fool
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
Special episode - Bluebird Bio: What went wrong? -December 2021: by P4A Let's Talk Rare
Will Bluebird Bio's Big Gamble Payoff? | Biotech Investing | Sick Economics
National Resilience forks over $110M for North Carolina manufacturing site in bluebird bio cell therapy partnership | Fierce Pharma
Opinion: Three tech, three biotech companies that are top takeover targets in 2019 - MarketWatch
The top 10 takeover targets in biopharma | Fierce Biotech
Bluebird bio snares gene-editing tech in $156M buyout deal | Fierce Biotech
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?
BLUEBIRDBIO
Bluebird Spinoff 2seventy Bio Gets Its Own Wings :: Scrip
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first | Fierce Pharma
BLUEBIRDBIO
bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A (NASDAQ:BLUE) | Seeking Alpha
Bristol-Myers' Acquisition of - GuruFocus.com
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 | Fierce Biotech
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Bluebird Bio $BLUE : r/HellsTradingFloor
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
